AI is revolutionizing the life sciences industry by creating breakthroughs from massive biological data using machine learning, integrating clinical records and different types of genomic data, discovering new medicine or drug targets, identifying new classes of cell types, performing diagnostics, and customizing clinical procedures in precision medicine. Artificial intelligence is comprised of several technologies, the most important of which are machine learning, deep learning, neural networks, natural language processing, and computer vision. There is a strong link between them, but the key technology is machine learning. Given that this technology may be exempt from patentability under some legislation, it is vital to develop additional policies to preserve intellectual property rights. As a result, various factors must be considered when preserving this technology and deciding how to preserve it.
Artificial Intelligence is a branch of computer science encompassing a wide range of methodologies to improve machines' ability to make data-driven judgments and accurate forecasts of events. AI is increasingly being examined and integrated into various scientific domains, particularly in the setting of Big Data. Due to their complexity and highly interdisciplinary character, life sciences offer several advantages for AI to impact R&D activities in various ways. The multiple areas where the life sciences industry uses AI are pharmaceutical research, pharmacology, drug discovery, Epidemiology, clinical investigations, Designing Clinical Trials, introducing robotic surgery, developing the next generation of radiology tools, Telemedicine, and clinical trials.
The global artificial intelligence in life sciences market size was calculated at USD 2.25 billion in 2024, to reach USD 2.71 billion in 2025 is expected to be worth USD 14.20 billion by 2034, expanding at a CAGR of 20.21% from 2024 to 2034. Technological advancements and growing demand for enhanced patient care are the major growth factors of the market.
Market participants in the AI in the life science industry are increasingly focusing on improving research studies of different body parts using AI and ML. Furthermore, research and development activities are key strategies used by market players to maintain their market position on a global scale.
Dr. Peter Dayan FRS, Director of Max Planck Institute for Biological Cybernetics, commented that science is constantly enjoying the introduction of new methodologies, from the microscope to computers, but the adoption is limited based on cost, availability of technology, and skills. He also said that machine learning is set to transform vast swathes of research.
Partner with our experts to explore the AI in Life Sciences Market at sales@towardshealthcare.com
